core revenu growth miss attribut weak mass spec sale us territori
changes/hir india time explan fail assuag fear competitive/
share loss outlook moder growth said like close
attract entri point assum mgm build convict issu transitori
 especi given buy-back plan
sale deriv via sale instrument instrument sale tend
record late quarter first time dynam result overal
result diverg street expect accordingli like prematur
assert long term outlook compani chang
said seemingli stress impact us sale forc chang way
heighten rather assuag concern littl explain peer
report much better result overlap busi geographi could
done better job share data fortifi convict assert issu
transitori thu could take bit time get stock narr back track
said chanc confluenc event could creat near-term buy
opportun least line peer averag revenu growth best-in-class margin
expect buy back compani market cap next year
think stock would begin becom attract price-to-earnings long term
investor still scream cheap absolute/histor basi
rel peer continu believ deserv premium multipl revis
price target base dcf analysi repres price-to-earnings nomin
premium peer multipl
core revenu growth consensu forecast manag
attribut weak mass spec under-perform india former
attribut sluggish start biomed research us territori realign
latter attribut linger gst implement headwind note mass spec
weak drove water divis instrument sale declin y/i
revenu grew hsd intra-quart commentari peer encourag
issu seemingli compani specif
read india india account sale
exposur india also indic india remain double-digit
growth market
exclud india sale biopharma grew china dd industrial/appli sale declin
attribut tough comparison territori align driven challeng
continu page
pleas see page report import disclosur
water remain one top life scienc tool compani fundament basi
compani post growth sever consecut year growth outlook
remain bright pharma appli market hope next sever year rate
share market perform price target base dcf analysi repres
price-to-earnings premium peer multipl
pharma grow msd
revenu grow drive
macroeconom competit
end market condit remain
grow organ
dd ep growth
higher expect oper leverag
growth sustain
current expect
great cash flow return profil
oper leverag lower level
anoth period slower expect
growth caus investor revisit
inher growth rate compani
corpor analyt instrument manufactur
divis design manufactur sell servic high-perform liquid
chromatographi hplc ultra perform liquid chromatographi uplc togeth
hplc refer lc mass spectrometri ms instrument system support
product includ chromatographi column consum product post-
warranti servic plan ta divis ta compani primarili design
manufactur sell servic thermal analysi rheometri calorimetri instrument
compani also develop supplier software-bas product interfac
compani instrument well manufactur instrument
impact mass spec sale chemic food environment custom ta
sale pure play industrial/cycl exposur grew china demand drove global
academic/govern sale growth total china growth biopharma
academ key driver north america grew us favor
comparison european sale grew moder growth attribut
industri academic/govern
gross margin came ahead expect better gross margin drove
oper margin line expect despit revenu miss non-
gaap ep beat forecast consensu rel
model lower expect tax rate ad ep clear
compani would miss consensu ep expect tax rate
manag reiter mid-singl digit constant currenc revenu growth
guidanc defin ep guidanc increas
vs prior guidanc constant currenc revenu growth guid
y/i ep first blush guidanc appear conserv
water divis instrument return lsd y/i growth midpoint
attain manag commentari order book quantit
encourag said core growth need approach order
meet mid-point fy growth guidanc base current known
manag announc new share repurchas program author ad
author previous remain allow
sustain higher level repurchas next year annual
flexibl purchas attract opportun present
compani report thomson eikon cowen compani
cowen vs consensu mm except msd cc fx y/i msd cc growth fx y/i less sell day y/i gross flat y/i revenu metric mm except statement mm except currenc per count beat forecast consensu exclud tailwind lower expect tax rate ep would miss divis revenu came forecast cc revenu growth y/i expect end market pharma y/i cc industrial/appli y/i cc acc/gov y/i cc expect overal compani instrument revenu declin y/i cc given solid overal ta growth seem like divis instrument declin geographi us y/i china solid grew well everi major region grow lsd best ta revenu came forecast cc revenu growth came better expect bright spot tough quarter streetaccount consensu revenu came forecast consensu constant currenc revenu growth y/i came expect fx tailwind y/i better expect primari driver miss appear divis instrument surpris given consist posit commentari peer end market gross margin came expect came slightli expect sg came expect though sale oper margin forecast line consensu larg due better expect gross margin lower expect tax rate ad ep cowen
compani report cowen compani
compani report thomson eikon cowen compani
mm except cagrcommentsnet cc fx y/yreport cc growth fx y/yorgan currenc re-affirmed leverag sg grown revenu oper growth sale growth re-affirmed non-oper interest re-affirmed tax earn per fx tailwind share dilut share count re-affirmed assum cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk upsid includ limit recoveri macroeconom condit
increas client budget demand lc/m instrument consum better
expect product innov associ revenu contribut share gain risk
downsid includ limit macroeconom deterior current
level inabl execut integr eros market share price due
competit inabl deliv incremental/decrement margin target value-
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock thermo fisher scientif secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
